Dapagliflozin in type 2 diabetes: Effectiveness across the spectrum of disease and over time

International Journal of Clinical Practice

Volumn 69, Issue 2, 2015, Pages 186-198

  Parikh, S ^a   Wilding, J ^b   Jabbour, S ^c   Hardy, E ^a  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; CHOLESTEROL; DAPAGLIFLOZIN; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; TRIACYLGLYCEROL; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN;

ADD ON THERAPY; ADULT; AGED; ALBUMINURIA; ARTICLE; BLOOD PRESSURE REGULATION; BODY WEIGHT; CEREBROVASCULAR ACCIDENT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEHYDRATION; DIET RESTRICTION; DIET THERAPY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXERCISE; FAINTNESS; FEMALE; GENITAL TRACT INFECTION; GLOMERULUS FILTRATION RATE; GLUCOSURIA; GLYCEMIC CONTROL; HEALTH CARE QUALITY; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; HYPOTENSION; HYPOVOLEMIA; INSULIN SENSITIVITY; KIDNEY CANCER; KIDNEY DISEASE; KIDNEY FAILURE; LIPID ANALYSIS; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORTHOSTATIC HYPOTENSION; PANCREAS ISLET BETA CELL; PHASE 3 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; RECOMMENDED DRUG DOSE; SPECTRUM; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS; URINARY TRACT INFECTION; VERY ELDERLY; WEIGHT REDUCTION; DIABETES MELLITUS, TYPE 2; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; MIDDLE AGED; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

ADULT; AGED; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

EID: 84921821459     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12531     Document Type: Article

References (49)

1. International Diabetes Federation. IDF Diabetes Altas, 6th Edition, 2014. http://www.idf.org/diabetesatlas/ (accessed 20 March 2011).
2. Prentice AM,. The emerging epidemic of obesity in developing countries. Int J Epidemiol 2006; 35: 93-9.
3. DeFronzo RA,. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773-95.
4. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-79.
5. Alvarez Guisasola F, Mavros P, Nocea G, et al. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study. Diabetes Obes Metab 2008; 10 (Suppl. 1): 8-15.
6. Cook MN, Girman CJ, Stein PP, Alexander CM,. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care. Diabet Med 2007; 24: 350-8.
7. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB,. Is glycemic control improving in U.S. adults? Diabetes Care 2008; 31: 81-6.
8. Bailey CJ, Kodack M,. Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract 2011; 65: 314-22.
9. Campbell RK,. Recommendations for improving adherence to type 2 diabetes mellitus therapy-focus on optimizing insulin-based therapy. Am J Manag Care 2012; 18: S55-61.
10. Mann DM, Ponieman D, Leventhal H, Halm EA,. Predictors of adherence to diabetes medications: the role of disease and medication beliefs. J Behav Med 2009; 32: 278-84.
11. Nau DP,. Recommendations for improving adherence to type 2 diabetes mellitus therapy-focus on optimizing oral and non-insulin therapies. Am J Manag Care 2012; 18: S49-54.
12. Nicolucci A, Rossi MC,. Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes. Acta Biomed 2008; 79: 184-91.
13. Han S, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008; 57: 1723-9.
14. Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008; 51: 1145-9.
15. Komoroski B, Vachharajani N, Feng Y, et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009; 85: 513-9.
16. Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009; 85: 520-6.
17. Rohwedder K, Hruba V, Salsali S, et al. Dapagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, Has a Low Propensity To Cause Hypoglycemia in Patients with Type 2 Diabetes. Diabetes 2011; 60 (Suppl. 1): A286.
18. Buse J,. Combining insulin and oral agents. Am J Med 2000; 108 (Suppl. 6a): 23S-32S.
19. Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012; 97: 1020-31.
20. Woo V, Langkilde AM, Sugg J, Parikh S,. Dapagliflozin, a Novel Antihyperglycemic Agent that Promotes Urinary Glucose Excretion, Reduces Systolic Blood Pressure in Patients with Type 2 Diabetes Mellitus [Abstract 9520]. Circulation 2011; 124: A9520.
21. Ferrannini E, Jimenez Ramos S, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Care 2010; 33: 2217-24.
22. Dapagliflozin: Highlights of Prescribing Information, 2014. http://packageinserts.bms.com/pi/pi-farxiga.pdf (accessed 23 March 2014).
23. Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 2223-33.
24. Rosenstock J, Vico M, Wei L, et al. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012; 35: 1473-8.
25. Strojek K, Yoon KH, Hruba V, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011; 13: 928-38.
26. Wilding JP, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med 2012; 156: 405-15.
27. Dapagliflozin: Summary of Product Characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002322/WC500136026.pdf (accessed 19 March 2014).
28. Woo V, Tang W, Salsali A, List JF,. Long-term Efficacy of Dapagliflozin Monotherapy in Patients with Type 2 Diabetes Mellitus. World Diabetes Congress, 4-8 December 2011, Dubai, UAE.
29. Bailey CJ, Gross JL, Hennicken D, et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med 2013; 11: 43.
30. Wilding JP, Woo V, Rohwedder K, et al. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab 2014; 16: 124-36.
31. Nauck MA, Prato SD, Durán-García S, et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus was inadequately controlled with metformin. Diabetes Obes Metab 2014; 16: 1111-1120.
32. Ptaszynska A, Johnsson KM, Apanovitch AM, et al. Safety of dapagliflozin in clinical trials for T2DM [Abstract 1011-P]. Diabetes 2012; 61: A258.
33. Johnsson KM, Ptaszynska A, Schmitz B, et al. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013; 27: 479-84.
34. Jabbour SA, Whaley JM, Tirmenstein M, et al. Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin. Postgrad Med 2012; 124: 62-73.
35. US Food and Drug Administration. FDA Background document, Dapagliflozin, Endocrinologic and Metabolic Drugs Advisory Committee Meeting, July 19, 2011. http://www.fda.gov/DOWNLOADS/ADVISORYCOMMITTEES/COMMITTEESMEETINGMATERIALS/DRUGS/ENDOCRINOLOGICANDMETABOLICDRUGSADVISORYCOMMITTEE/UCM262994.PDF (accessed 06 June 2014).
36. Henry RR, Murray AV, Marmolejo MH, et al. Dapagliflozin, metformin-XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 2012; 66: 446-56.
37. Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011; 34: 2015-22.
38. Macdonald FR, Peel JE, Jones HB, et al. The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab 2010; 12: 1004-12.
39. Mudaliar S, Henry RR, Boden G, et al. Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. Diabetes Technol Ther 2014; 16: 137-44.
40. National Institute for Health and Care Excellence. Obesity guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children: NICE clinical guideline 43, 2006. http://www.nice.org.uk/nicemedia/pdf/CG43NICEGuideline.pdf (accessed 19 March 2014).
41. Fonseca VA,. Defining and characterizing the progression of type 2 diabetes. Diabetes Care 2009; 32 (Suppl. 2): S151-6.
42. Johnsson KM, Ptaszynska A, Schmitz B, et al. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013; 27: 473-8.
43. List JF, Whaley JM,. Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans. Kidney Int Suppl 2011; 79: S20-7.
44. Hardy E, Ptaszynska A, DeBruin T, et al. Dapagliflozin Effects on the Lipid Profile of Patients with Type 2 Diabetes Mellitus [poster #1188-P]. 73rd Scientific Sessions-American Diabetes Association, 21-25 June 2013, Chicago, IL, USA.
45. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013; 159: 262-74.
46. Musso G, Gambino R, Cassader M, Pagano G,. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 2012; 44: 375-93.
47. Vigneri P, Frasca F, Sciacca L, et al. Diabetes and cancer. Endocr Relat Cancer 2009; 16: 1103-23.
48. AstraZeneca. Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58). http://clinicaltrials.gov/show/NCT01730534 (accessed 26 March 2014).
49. Summaries for patients: Dapagliflozin treatment in patients with inadequately controlled type 2 diabetes despite the use of insulin. Ann Intern Med 2012; 156: I-44.